PMID- 27933192
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 2053-3624 (Print)
IS  - 2053-3624 (Electronic)
IS  - 2053-3624 (Linking)
VI  - 3
IP  - 2
DP  - 2016
TI  - Randomised comparison of drug-eluting versus bare-metal stenting in patients with 
      non-ST elevation myocardial infarction.
PG  - e000455
LID - e000455
AB  - OBJECTIVE: The superiority of drug-eluting stents (DES) over bare-metal stents 
      (BMS) in patients with ST elevation myocardial infarction (STEMI) is well 
      studied; however, randomised data in patients with non-ST elevation myocardial 
      infarction (NSTEMI) are lacking. The objective of this study was to investigate 
      whether stenting with everolimus-eluting stents (EES) safely reduces restenosis 
      in patients with NSTEMI as compared to BMS. METHODS: ELISA-3 patients were asked 
      to participate in the angiographic substudy and were randomised to DE (Xience V) 
      or BM (Vision) stenting (ELISA-3 group). The primary end point was minimal 
      luminal diameter (MLD) at 9-month follow-up angiography. In addition, 296 
      patients with NSTEMI who were excluded or did not want to participate in the 
      ELISA-3 trial (RELI group) were randomised to DE or BM stenting and underwent 
      clinical follow-up only (major adverse cardiac events (MACE), stent thrombosis 
      (ST)). A pooled analysis was performed to assess an effect on clinical outcome. 
      RESULTS: 178 of 540 ELISA-3 patients participated in the angiographic substudy. 
      MLD at 9 months angiography was 2.37+/-0.63 mm (DES) versus 1.84+/-0.62 mm (BMS), 
      p<0.001. Binary restenosis occurred in 1.9% in the DES group versus 16.7% in the 
      BMS group (RR 0.11, 95% CI 0.02 to 0.84, p=0.007). In the pooled analysis, the 
      incidence of MACE, target vessel revascularisation and ST at 2 years follow-up in 
      the DES versus BMS group was 12.5% versus 16.0% (p=0.28), 4.0% versus 10.4% 
      (p=0.009) and 1.3% versus 3.0% (p=0.34), respectively. CONCLUSIONS: In patients 
      with NSTEMI, use of EES is safe and decreases both angiographic and clinical 
      restenosis as compared to BMS http://www.isrctn.com/search?q=39230163. TRIAL 
      REGISTRATION NUMBER: 39230163; Post-results.
FAU - Remkes, Wouter S
AU  - Remkes WS
AD  - Isala heart centre , Zwolle , The Netherlands.
FAU - Badings, Erik A
AU  - Badings EA
AD  - Deventer Ziekenhuis , Deventer , The Netherlands.
FAU - Hermanides, Renicus S
AU  - Hermanides RS
AD  - Isala heart centre , Zwolle , The Netherlands.
FAU - Rasoul, Saman
AU  - Rasoul S
AD  - Maastricht University Medical Center , Maastricht , The Netherlands.
FAU - Dambrink, Jan-Henk E
AU  - Dambrink JE
AD  - Isala heart centre , Zwolle , The Netherlands.
FAU - Koopmans, Petra C
AU  - Koopmans PC
AD  - Isala heart centre , Zwolle , The Netherlands.
FAU - The, Salem Hk
AU  - The SH
AD  - Ziekenhuis Bethesda , Hoogeveen , The Netherlands.
FAU - Ottervanger, Jan Paul
AU  - Ottervanger JP
AD  - Isala heart centre , Zwolle , The Netherlands.
FAU - Gosselink, A T Marcel
AU  - Gosselink AT
AD  - Isala heart centre , Zwolle , The Netherlands.
FAU - Hoorntje, Jan Ca
AU  - Hoorntje JC
AD  - Maastricht University Medical Center , Maastricht , The Netherlands.
FAU - Suryapranata, Harry
AU  - Suryapranata H
AD  - Isala heart centre, Zwolle, The Netherlands; Radboud University Nijmegen Medical 
      Center, Nijmegen, The Netherlands.
FAU - van 't Hof, Arnoud Wj
AU  - van 't Hof AW
AD  - Isala heart centre , Zwolle , The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161117
PL  - England
TA  - Open Heart
JT  - Open heart
JID - 101631219
CIN - Open Heart. 2016 Nov 24;3(2):e000536. PMID: 27942047
PMC - PMC5133402
COIS- EAB received consulting fees from Merck Sharp and Dohme and Sanofi-Aventis. AWJv 
      H received speaker's fees and research grants from Merck, Sanofi-Aventis, The 
      Medicines Company, Iroko Cardio and AstraZeneca.
EDAT- 2016/12/10 06:00
MHDA- 2016/12/10 06:01
PMCR- 2016/11/17
CRDT- 2016/12/10 06:00
PHST- 2016/04/18 00:00 [received]
PHST- 2016/07/25 00:00 [revised]
PHST- 2016/09/06 00:00 [accepted]
PHST- 2016/12/10 06:00 [entrez]
PHST- 2016/12/10 06:00 [pubmed]
PHST- 2016/12/10 06:01 [medline]
PHST- 2016/11/17 00:00 [pmc-release]
AID - openhrt-2016-000455 [pii]
AID - 10.1136/openhrt-2016-000455 [doi]
PST - epublish
SO  - Open Heart. 2016 Nov 17;3(2):e000455. doi: 10.1136/openhrt-2016-000455. 
      eCollection 2016.